F
Felix Reyes
Researcher at French Institute of Health and Medical Research
Publications - 138
Citations - 17133
Felix Reyes is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Lymphoma & International Prognostic Index. The author has an hindex of 51, co-authored 138 publications receiving 16525 citations. Previous affiliations of Felix Reyes include University of Paris.
Papers
More filters
Journal ArticleDOI
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
Bertrand Coiffier,Eric Lepage,Josette Brière,Raoul Herbrecht,Hervé Tilly,Reda Bouabdallah,Pierre Morel,Eric Van Den Neste,Gilles Salles,Philippe Gaulard,Felix Reyes,Pierre Lederlin,Christian Gisselbrecht +12 more
TL;DR: A randomized trial to compare CHOP chemotherapy plus rituximab with CHOP alone in elderly patients with diffuse large-B-cell lymphoma found the rate of complete response was significantly higher in the group that received CHOP plus r ituximabs than in thegroup that receivedCHOP alone.
Journal ArticleDOI
Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte
P. Feugier,A. Van Hoof,Catherine Sebban,Philippe Solal-Celigny,R. Bouabdallah,Christophe Fermé,B. Christian,Eric Lepage,H. Tilly,F. Morschhauser,Philippe Gaulard,Gilles Salles,André Bosly,Christian Gisselbrecht,Felix Reyes,B. Coiffier +15 more
TL;DR: Using the combination of R-CHOP leads to significant improvement of the outcome of elderly patients with diffuse large B-cell lymphoma, with significant survival benefit maintained during a 5-year follow-up.
Journal ArticleDOI
Rituximab (Anti-CD20 Monoclonal Antibody) for the Treatment of Patients With Relapsing or Refractory Aggressive Lymphoma: A Multicenter Phase II Study
B. Coiffier,Corinne Haioun,Nicolas Ketterer,Andreas Engert,H. Tilly,David D.F. Ma,Peter Johnson,Andrew Lister,M. Feuring Buske,John Radford,R. Capdeville,Volker Diehl,Felix Reyes +12 more
TL;DR: In this first trial of rituximab in DLCL and MCL, patients experienced a significant clinical activity with a low toxicity and should be tested in combination with chemotherapy in such patients.
Journal ArticleDOI
Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).
Nicolas Mounier,Josette Brière,Christian Gisselbrecht,Jean-François Emile,Pierre Lederlin,Catherine Sebban,Françoise Berger,André Bosly,Pierre Morel,Hervé Tilly,Reda Bouabdallah,Felix Reyes,Philippe Gaulard,Bertrand Coiffier +13 more
TL;DR: Rituximab is able to prevent chemotherapy failure in patients with bcl-2 protein overexpression, and is associated with a better overall survival and event-free survival than R-CHOP in b cl-2+ patients.
Journal ArticleDOI
[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome
Corinne Haioun,Emmanuel Itti,Alain Rahmouni,Pauline Brice,Jean-Didier Rain,Karim Belhadj,Philippe Gaulard,Laurent Garderet,Eric Lepage,Felix Reyes,Michel Meignan +10 more
TL;DR: Predictive value of "early PET" was observed in both the lower-risk and higher-risk groups, indicating prognostic independence from the IPI, and FDG-PET should be an early guide to first-line strategies in aggressive lymphoma.